Weber B P, Lai W K, Dillier N, von Wallenberg E L, Killian M J P, Pesch J, Battmer R D, Lenarz T
Department of Otorhinolaryngology, University Hospital, Zürich, Switzerland.
Ear Hear. 2007 Apr;28(2 Suppl):46S-48S. doi: 10.1097/AUD.0b013e3180315442.
Cochlear recently released the Nucleus Freedom System which has been based on the Nucleus Research Platform 8. Both systems make use of the same implant, the CI24RE, which includes expanded total stimulation rates up to 32 kHz. In this study the performance of the ACE strategy at 500, 1200 and 3500 pps/channel was investigated using an ABC-CBA design. At the end of each period speech tests were performed. In the CBA phase the patients completed a comparative questionnaire to determine the subjective rate preference. Preliminary results in 13 recipients indicate no differences in for the ACE strategy at rates ranging from 500 pps to 3500 pps/channel.
科利耳公司最近发布了基于Nucleus研究平台8的Nucleus Freedom系统。这两个系统都使用相同的植入体CI24RE,其总刺激率最高可扩展至32千赫。在本研究中,采用ABC-CBA设计对500、1200和3500脉冲每秒/通道的ACE策略性能进行了研究。在每个阶段结束时进行言语测试。在CBA阶段,患者完成一份比较问卷以确定主观速率偏好。13名接受者的初步结果表明,在500脉冲每秒至3500脉冲每秒/通道的速率范围内,ACE策略没有差异。